RT Journal Article
SR Electronic
T1 Poor Prognosis in Patients With Stage III Colorectal Cancer Receiving Adjuvant FOLFOX/CAPOX Therapy Is Predicted by the Presence of Many Poorly Differentiated Clusters
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3235
OP 3240
DO 10.21873/anticanres.16497
VO 43
IS 7
A1 YOSHIMATSU, KAZUHIKO
A1 KONO, TEPPEI
A1 SATAKE, MASAYA
A1 ITO, YOSHITOMO
A1 SHIOZAWA, SHUNICHI
A1 TANAKA, HIRONORI
A1 HIGASHIDA, MASAHARU
A1 OKADA, TOSHIMASA
A1 ENDO, SHUJI
A1 FUJIWARA, YOSHINAORI
A1 UENO, TOMIO
YR 2023
UL http://ar.iiarjournals.org/content/43/7/3235.abstract
AB Background/Aim: Poorly differentiated clusters (PDCs) have been reported to be a useful grading system for predicting prognosis in patients with colorectal cancer (CRC). We investigated the association between the number of PDCs and prognosis in patients with stage III CRC treated with oxaliplatin-based adjuvant chemotherapy. Patients and Methods: This is a retrospective study of 49 patients with stage III CRC who underwent curative surgery followed by oxaliplatin-based adjuvant chemotherapy. PDC was defined as a cluster of ≥5 cancer cells without glandular structure at the invasive front of the primary tumor. Results: During the observation period, 12 patients experienced relapse. The patients were divided into two groups (<7 and ≥7 PDC groups), and receiver operating characteristic (ROC) curves were calculated [area under the curve (AUC)=0.743]. Patients with ≥7 PDCs had a much shorter relapse-free survival (RFS) than those with <7 PDCs (p<0.0001). The overall survival (OS) was also significantly worse in patients with ≥7 PDCs than in those with <7 PDCs (p<0.0001). Multivariate analysis revealed that PDC was the only significant prognostic factor measured that could predict RFS (p=0.002) and OS (p=0.0047) in patients with stage III CRC treated with oxaliplatin-based adjuvant chemotherapy. Conclusion: In patients with stage III CRC treated with post-resection oxaliplatin-based adjuvant chemotherapeutic regimens, the presence of ≥7 PDCs at the invasive front of the primary tumor predicted unfavorable prognosis.